Published in Arch Med Sci on April 22, 2013
Long-term persistence with anti-osteoporosis drugs after fracture. Osteoporos Int (2015) 0.85
Chosen risk factors for osteoporosis and the level of knowledge about the disease in peri- and postmenopausal women. Prz Menopauzalny (2015) 0.83
Impact of patient programs on adherence and persistence in inflammatory and immunologic diseases: a meta-analysis. Patient Prefer Adherence (2015) 0.81
Vitamin D receptor BsmI polymorphism and osteoporosis risk in post-menopausal women. Arch Med Sci (2016) 0.80
Evaluation of the quality of life of postmenopausal osteoporotic and osteopenic women with or without fractures. Arch Med Sci (2015) 0.76
Knowledge about osteoporosis prevention among women screened by bone densitometry. Prz Menopauzalny (2016) 0.75
Evaluation of a "Just-in-Time" Nurse Consultation on Bone Health: A Pilot Randomized Controlled Trial. Perm J (2017) 0.75
A systematic review of the associations between dose regimens and medication compliance. Clin Ther (2001) 9.23
A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int (2007) 3.50
Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev (2002) 3.46
Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91
The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int (2004) 2.88
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin (2005) 2.57
Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev (2002) 2.49
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2006) 1.79
Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ (2006) 1.74
Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int (2003) 1.72
Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev (2002) 1.62
Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev (2002) 1.53
Tolerability and compliance with risedronate in clinical practice. Osteoporos Int (2003) 1.51
Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res (2008) 1.47
Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev (2002) 1.34
Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin (2006) 1.32
Patient education in groups increases knowledge of osteoporosis and adherence to treatment: a two-year randomized controlled trial. Patient Educ Couns (2010) 1.22
The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther (2006) 1.16
Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med (2006) 1.11
Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int (2003) 1.09
A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin (2007) 1.08
Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int (2010) 1.07
Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trial. Am J Manag Care (2009) 0.94
Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life. Med Sci Monit (2011) 0.91
Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract (2006) 0.90
Medication adherence: a challenge for patients with postmenopausal osteoporosis and other chronic illnesses. J Manag Care Pharm (2006) 0.89
Risk of hip fracture in Poland. Med Sci Monit (2007) 0.89
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int (2006) 0.89
Does serum osteoprotegerin level relate to fragility fracture in elderly women with low vitamin D status? Med Sci Monit (2010) 0.88
Understanding patient compliance and persistence with osteoporosis therapy. Drugs Aging (2011) 0.88
Osteoporosis medication profile preference: results from the PREFER-US study. Health Expect (2007) 0.87
Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss. Maturitas (2008) 0.86
Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women. Curr Med Res Opin (2007) 0.82
Compliance with alendronate 10 treatment in elderly women with postmenopausal osteoporosis. Endokrynol Pol (2009) 0.81
Alendronate 70 therapy in elderly women with post-menopausal osteoporosis: the problem of compliance. Endokrynol Pol (2011) 0.81
Vitamin D receptor gene polymorphisms, bone mineral density and fractures in postmenopausal women with osteoporosis. Mol Biol Rep (2012) 0.96
Polymorphism of VDR gene--the most effective molecular marker of osteoporotic bone fractures risk within postmenopausal women from Wielkopolska region of Poland. Endokrynol Pol (2005) 0.87
Association analysis of the polymorphisms of the VDR gene with bone mineral density and the occurrence of fractures. J Bone Miner Metab (2007) 0.85
Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis. J Clin Endocrinol Metab (2013) 0.84
Correlation of vitamin D receptor gene (VDR) polymorphism with osteoporotic changes in Polish postmenopausal women. Neuro Endocrinol Lett (2009) 0.83
Association analysis of vitamin D receptor gene polymorphisms with bone mineral density in young women with Graves' disease. Acta Biochim Pol (2008) 0.82
Alendronate 70 therapy in elderly women with post-menopausal osteoporosis: the problem of compliance. Endokrynol Pol (2011) 0.81
[The course of a multipara's pregnancy, labour and puerperium complicated by spleen tumor]]. Ginekol Pol (2003) 0.77
Bisphosphonates and the risk of atrial fibrillation. Endokrynol Pol (2011) 0.77
FRAX calculator and Garvan nomogram in male osteoporotic population. Aging Male (2014) 0.77
Influence of social competence of physicians on patient compliance with osteoporosis medications--a study on Polish postmenopausal women. Ginekol Pol (2012) 0.77
The effects of melatonin on glutathione peroxidase activity in serum and erythrocytes after adriamycin in normal and pinealectomised rats. Endokrynol Pol (2008) 0.77
Assessment of OPG, RANKL, bone turnover markers serum levels and BMD after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis. Endokrynol Pol (2016) 0.76
The role of i.v. ibandronate administration in osteoporosis therapy. Endokrynol Pol (2011) 0.76
Correlations between 10-year risk of death from cardiovascular diseases and 10-year osteoporotic fracture risk in postmenopausal women. Endokrynol Pol (2017) 0.75
[The role of i.v. ibandronate administration in osteoporosis therapy]. Endokrynol Pol (2011) 0.75
Preliminary dielectric studies of knee swelling fluid in the case of arthritis, which is hard to diagnose. Physiol Meas (2006) 0.75
[Bisphosphonates and the risk of atrial fibrillation]. Endokrynol Pol (2011) 0.75
Nanocapsules templated on liquid cores stabilized by graft amphiphilic polyelectrolytes. Nanoscale (2015) 0.75
Renal Artery Stenting Associated With Improvement in Renal Function and Blood Pressure Control in Long-Term Follow-Up. Kidney Blood Press Res (2016) 0.75
Evaluation of vitamin D concentration in a population of young, healthy women - effects of vitamin D supplementation. Endokrynol Pol (2017) 0.75